계명대학교 의학도서관 Repository

Efficacy and Safety of Coadministered Ezetimibe-Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial

Metadata Downloads
Author(s)
Zhao-Yan SongMoo-Hyun KimHan-Cheol LeeSung-Ji ParkMoo-Yong RheeJong-Il ChoiSang-Hyun KimIn-Ho ChaeYoung-Joon HongNam-Ho LeeGyo-Seung HwangSeung-Ho HurJung-Woo SonJei-Keon ChaeHyo-Soo Kim
Keimyung Author(s)
Hur, Seung Ho
Department
Dept. of Internal Medicine (내과학)
Journal Title
J Clin Med
Issued Date
2023
Volume
12
Issue
6
Keyword
dyslipidemiaezetimibehypertensionrosuvastatintelmisartan
Abstract
Background:
The introduction of a fixed-dose combination (FDC) is expected to improve treatment compliance.

Methods:
There were 181 subjects who were randomized to three groups: ezetimibe-rosuvastatin 10/20 mg + telmisartan 80 mg, ezetimibe-rosuvastatin 10/20 mg, and telmisartan 80 mg. The primary outcomes were change in mean sitting systolic blood pressure (MSSBP) and percentage change in low-density-lipoprotein cholesterol (LDL-C) compared to baseline at week 8.

Results:
The least-square mean (SE) in MSSBP changes between the ezetimibe-rosuvastatin 10/20 mg + telmisartan 80 mg group and the ezetimibe-rosuvastatin 10/20 mg group were -25.81 (2.34) mmHg and -7.66 (2.45) mmHg. There was a significant difference between the two groups (-18.15 (2.83) mmHg, 95% CI -23.75 to -12.56, p < 0.0001). Changes in least-square mean (SE) in LDL-C between the ezetimibe-rosuvastatin 10/20 mg + telmisartan 80 mg group and the telmisartan 80 mg group were -63.82 (2.87)% and -2.48 (3.12)%. A significant difference was observed between the two groups (-61.34 (3.33)%, 95% CI -67.91 to -54.78, p < 0.0001). No serious adverse events were observed.

Conclusions:
Ezetimibe-rosuvastatin plus telmisartan treatment is effective and safe when compared to either ezetimibe-rosuvastatin or telmisartan.
Keimyung Author(s)(Kor)
허승호
Publisher
School of Medicine (의과대학)
Type
Article
ISSN
2077-0383
Source
https://www.mdpi.com/2077-0383/12/6/2377
DOI
10.3390/jcm12062377
URI
https://kumel.medlib.dsmc.or.kr/handle/2015.oak/44988
Appears in Collections:
1. School of Medicine (의과대학) > Dept. of Internal Medicine (내과학)
공개 및 라이선스
  • 공개 구분공개
파일 목록

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.